Recently, biomarkers related to bone metabolism, such as IGF-1 and osteocalcin, have shown significant potential in the early diagnosis, subtype classification, and assessment of therapeutic efficacy in girls with CPP (28, 29, 30). This evidence concerns the gene BGLAP and central precocious puberty.